Regeneron's Otarmeni Approved as First Gene Therapy for Hearing Loss

FDA approves Regeneron's Otarmeni — the first gene therapy for genetic hearing loss — as Regeneron closes the 17th and final White House MFN pricing deal. Roche calls giredestrant its potentially largest product ever, Novo Nordisk's 72% decline deepens, AbbVie commits $1.4B to North Carolina.Visit us at www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drug approvals, healthcare, pharma podcast, The Pharma Closeout, Regeneron, Otarmeni, gene therapy, hearing loss, FDA approval, MFN pricing, White House, Roche, giredestrant, breast cancer, Novo Nordisk, oral semaglutide, Foundayo, orforglipron, AbbVie, Durham, manufacturing, Rigel, Eli Lilly, RIPK1, Grace Therapeutics, GTX-104, nimodipine, Sanofi, Dupixent, Novartis, radioligand therapy, GE HealthCare, LUMINA, Tempero, Amgen, Inovio, Lilly